The global diamond-blackfan anemia (DBAAASE) syndrome therapeutics market is on the brink of substantial growth, according to recent market projections. This market, focused on treatments for Diamond-Blackfan Anemia (DBA), a rare genetic disorder, is expected to expand at a robust compound annual growth rate (CAGR) of 4.2% from 2023 to 2033. The industry’s value is projected to soar from USD 4.8 billion in 2023 to an impressive USD 7.29 billion by 2033.
DBA is characterized by hematologic issues, primarily affecting red blood cell production, and is most commonly diagnosed within the first year of life. The rising prevalence of DBA cases globally is a significant driver of growth in the DBAAASE therapeutics market. This expansion is fueled by increased awareness and diagnosis of DBA, along with advancements in treatment options and supportive care.
Get Sample Reports Diamond-Blackfan Anemia (DBAAASE) Syndrome Therapeutics Market
Factors such as shifting lifestyles, increased government funding for research and development initiatives, and rapid technological advancements are expected to further propel market expansion over the forecast period. These developments underscore the growing importance of addressing unmet medical needs and advancing therapeutic options for individuals affected by DBA.
The rising demand for innovative treatment modalities and the emergence of novel therapeutic approaches are anticipated to drive substantial investments in research and development activities, fostering collaborations between industry players, academic institutions, and government organizations.
As the global DBAAASE therapeutics market continues to evolve, stakeholders are urged to leverage strategic partnerships and investments to capitalize on emerging opportunities, ultimately contributing to improved patient outcomes and enhanced quality of life for individuals living with DBA.
Key Takeaways from the Market Study:
- Global DBAAASE syndrome therapeutics market to expand 1.5x from 2023 to 2033
- By treatment, blood transfusions to experience a growth rate of 6.9%
- Around 2 out of 5 DBAAASE syndrome therapeutics to happen across North America
- Europe to emerge as an important contributor, expected to surge at a CAGR of 3.7%
- Treatment through corticosteroids to gain equal traction as blood transfusions
“As medical science expands, treatments and therapies for a broad range of blood disorders is gaining major traction. This is boding well for the market on diamond blackfan anemia syndrome, with healthcare providers introducing a plethora of therapies and treatment approaches,” says an FMI analyst.
Discover Key Insights Request Full Report Access Now
Key Market Players
Key players in the Diamond–Blackfan Anemia (DBA)/Aase Syndrome Therapeutics market are
- Sumitomo Corporation
- Johnson & Johnson Private Limited
- Novartis AG
- Pfizer Inc.
- Sanofi S.A
- Merck & Co. Inc.
- LEO Pharma A/S
- Cipla Limited
- GSK Plc.
- AstraZeneca Plc.
- Abbott Laboratories
- Bayer AG
Recent Development:
- In July 2021, AstraZeneca procured Alexion Pharmaceuticals, a global biotech company. With this acquisition, the company will be able to enter the market for rare disease medicines, ushering in a new chapter. Moreover, the acquisition strengthened AstraZeneca’s scientific presence in immunology and would allow the company to continue to pioneer the discovery and development of medicines for patients with rare diseases using Alexion’s new complement-biology system and robust pipeline.
- In June 2022, Pfizer will collaborate with Sirana Pharma, a biotechnology company. The collaboration would help Pfizer recognize and validate a novel therapeutic concept for unique and severe bone diseases.
Key Segments Profiled in the Diamond–Blackfan Anemia (DBAAASE) Syndrome Therapeutics Industry Survey:
By Treatment:
- Corticosteroids
- Chelation Therapy
- Blood Transfusions
- Stem Cell Transplant
- Others
By End User:
- Hospitals
- Clinics
- Others
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
